Literature DB >> 10405750

Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis--CT and US features.

N A Avila1, A J Dwyer, J K Dale, U A Lopatin, M C Sneller, E S Jaffe, J M Puck, S E Straus.   

Abstract

PURPOSE: To describe the imaging findings in patients with autoimmune lymphoproliferative syndrome (ALPS) and to relate the findings to the clinical and genetic features of this recently recognized syndrome.
MATERIALS AND METHODS: Retrospective or prospective reviews of the computed tomographic (CT) and ultrasonographic (US) studies and the clinical features in 19 consecutive patients with ALPS were performed.
RESULTS: Most patients presented in the 1st year of life with symptoms of adenopathy and hepatosplenomegaly. At the time of presentation to the institution, 12 patients had already undergone splenectomy, and 14 patients had developed autoimmune disorders. All patients had multifocal adenopathy, which was massive in some patients; 14 of 15 patients who underwent CT of the chest had an enlarged thymus, and all six patients who retained their spleens and who underwent imaging had splenomegaly. Ten of 18 patients who underwent liver imaging had hepatomegaly. The adenopathy at US was hyper- and/or isoechoic relative to the liver and thyroid and was enhanced at CT in some patients. All patients had defective lymphocytic apoptosis, or programmed cell death, which was due to specific Fas (APT1 [TNFRSF6]) mutations in 15 patients.
CONCLUSION: Patients with ALPS demonstrate nonspecific but often dramatic imaging findings of lymphoproliferative disorders, such as adenopathy, splenomegaly, thymic enlargement, and hepatomegaly. The stability of the clinical findings over months to years and the pattern of lymph node echogenicity may suggest the diagnosis of ALPS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405750     DOI: 10.1148/radiology.212.1.r99jl40257

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

Review 1.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

2.  Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.

Authors:  Kennichi C Dowdell; Julie E Niemela; Susan Price; Joie Davis; Ronald L Hornung; João Bosco Oliveira; Jennifer M Puck; Elaine S Jaffe; Stefania Pittaluga; Jeffrey I Cohen; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2010-04-01       Impact factor: 22.113

3.  Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.

Authors:  Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

4.  18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.

Authors:  Jorge A Carrasquillo; Clara C Chen; Susan Price; Millie Whatley; Nilo A Avila; Stefania Pittaluga; Elaine S Jaffe; V Koneti Rao
Journal:  Clin Nucl Med       Date:  2019-12       Impact factor: 7.794

Review 5.  Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management.

Authors:  Jutte van der Werff ten Bosch
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  Kennichi C Dowdell; Lesley Pesnicak; Victoria Hoffmann; Kenneth Steadman; Alan T Remaley; Jeffrey I Cohen; Stephen E Straus; V Koneti Rao
Journal:  Exp Hematol       Date:  2009-02-12       Impact factor: 3.084

Review 7.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.